Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma

Expert Review of Neurotherapeutics

Volumn 6, Issue 5, 2006, Pages 635-652

  Green, Myke R ^a   Chowdhary, Sajeel ^a   Lombardi, Kristina M ^a   Chalmers, Lisa M ^a   Chamberlain, Marc ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

High dose methotrexate; Non Hodgkin's lymphoma; Primary CNS lymphoma

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; AMIODARONE; ASPARAGINASE; BLEOMYCIN; CARMUSTINE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; DOXYCYCLINE; FOLINIC ACID; HYDROCHLOROTHIAZIDE; HYDROXYUREA; LIVE VACCINE; LOMUSTINE; MERCAPTOPURINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PENICILLIN G; PHENYTOIN; PREDNISOLONE; PROBENECID; PROCARBAZINE; RETINOID; UNINDEXED DRUG; VINCRISTINE; ANTINEOPLASTIC ANTIMETABOLITE;

ALOPECIA; ANEMIA; APOPTOSIS; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOTHERAPY; CLINICAL TRIAL; DESQUAMATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; EPIDERMOLYSIS; ERYTHEMA MULTIFORME; GASTROINTESTINAL TOXICITY; HUMAN; INCIDENCE; LEUKOPENIA; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NONHODGKIN LYMPHOMA; PRURITUS; RASH; REVIEW; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; URTICARIA; CENTRAL NERVOUS SYSTEM TUMOR; DOSE RESPONSE; LYMPHOMA; TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; CENTRAL NERVOUS SYSTEM NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LYMPHOMA; METHOTREXATE; TREATMENT OUTCOME;

EID: 33745105697     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.5.635     Document Type: Review

References (146)

1. Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer 29, 252-260 (1972).
2. Fine HA, Mayer RJ. Primary central nervous system lymphoma. Ann. Intern. Med. 119, 1093-1104 (1993).
3. Miller DC, Hochberg FH, Harris NL, Gruber ML, Louis DN, Cohen H. Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The Massachusetts General Hospital experience 1958-1989. Cancer 74, 1383-1397 (1994).
4. Hochberg FH, Miller DC. Primary central nervous system lymphoma. J. Neurosurg. 68(6), 835-853 (1988).
5. Corn BW, Marcus SM, Topham A, Hauck W, Curran WJ Jr. Will Central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000? Cancer 79, 2409-2413 (1997).
6. Ahsan H, Neugut AI, Bruce JN. Trends in incidence of primary malignant brain tumors in USA, 1981-1990. Int. J. Epidemiol. 24, 1078-1085 (1995).
7. Schabet M. Epidemiology of primary CNS lymphoma. J. Neurooncol. 43, 199-201 (1999).
8. Olson JE, Janney CA, Rao RD et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma. Cancer 95, 1504-1510 (2002).
9. Krogh-Jensen M, D'Amore F, Jensen MK et al. Clinicopathological features, survival and prognostic factors of primary central nervous system lymphomas: Trends in incidence of primary central nervous system lymphomas and primary malignant brain tumors in a well-defined geographical area. Population-based data from the Danish lymphoma Registry, LYFO, and the Danish cancer Registry. Leuk. Lymphoma 19, 223-233 (1995).
10. Krogh-Jensen M, d'Amore F, Jensen MK et al. Incidence, clinicopathological features and outcome of primary central nervous system lymphomas. Population-based data from a Danish lymphoma registry. Danish Lymphoma Study Group, LYFO. Ann. Oncol. 5, 349-354 (1994).
11. Plotkin SR, Batchelor TT. Primary nervous-system lymphoma. Lancet Oncol. 2, 354-365 (2001).
12. Ferreri AJ, Abrey LE, Blay JY et al. Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, e12 to 15, 2002. J. Clin. Oncol. 21, 2407-2414 (2003).
13. Sonstein W, Tabaddor K, Llena JF. Solitary primary CNS lymphoma: long term survival following total resection. Med. Oncol. 15, 61-65 (1998).
14. Herrlinger U, Schabet M, Clemens M et al. Clinical presentation and therapeutic outcome in 26 patients with primary CNS lymphoma. Acta. Neurol. Scand. 97, 257-264 (1998).
15. Ferracini R. Primary malignant non-Hodgkin's lymphomas of the central nervous system in immunocompetent patients: diagnostic, prognostic and therapeutic criteria. Pathologica 89, 146-154 (1997).
16. Bromberg JE, Siemers MD, Taphoorn MJ. Is a "vanishing tumor" always a lymphoma? Neurology 59, 762-764 (2002).
17. Nelson DF, Martz KL, Bonner H et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG), RTOG 8315. Int. J. Radiat. Oncol. Biol. Phys. 23, 9-17 (1992).
18. Mead GM, Bleehen NM, Gregor A et al. A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer 89, 1359-1370 (2000).
19. Nguyen PL, Chakravarti A, Finkelstein DM, Hochberg FH, Batchelor TT, Loeffler JS. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J. Clin. Oncol. 23, 1507-1513 (2005).
20. Omuro AM, Ben-Porat LS, Panageas KS et al. Delayed neurotoxicity in primary central nervous system lymphoma. Arch. Neurol. 62, 1595-1600 (2005).
21. DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. Radiation Therapy Oncology Group Study 93-10. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: radiation therapy oncology group study 93-10. J. Clin. Oncol. 20, 4643-4648 (2002).
22. DeAngelis LM. Primary central nervous system lymphoma: a curable brain tumor. J. Clin. Oncol. 21, 4471-4473 (2003).
23. Fine HA. Primary central nervous system lymphoma: time to ask the question. J. Clin. Oncol. 20, 4615-4617 (2002).
24. O'Neill BP, O'Fallon JR, Earle JD, Colgan JP, Brown LD, Krigel RL. Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy? Int. J. Radiat. Oncol. Biol. Phys. 33, 663-673 (1995).
25. Schultz C, Scott C, Sherman W et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J. Clin. Oncol. 14, 556-564 (1996).
26. Shenkier TN, Voss N, Chhanabhai M et al. The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Columbia Cancer Agency. Cancer 103, 1008-1017 (2005).
27. Blay JY. Primary cerebral non-Hodgkin's lymphoma in non-immunocompromised Subjects. Bull. Cancer 84, 976-980 (1997).
28. Pech IV, Peterson K, Cairncross JG. Chemotherapy for brain tumors. Oncology 12, 537-553 (1998).
29. Ferreri AJ, Reni M, Villa E. Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials. Ann. Oncol. 11, 927-937 (2000).
30. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J. Clin. Oncol. 16, 859-863 (1998).
31. Cher L, Glass J, Harsh GR, Hochberg FH. Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: preliminary results. Neurology 46, 1757-1759 (1996).
32. Dahlborg SA, Petrillo A, Crossen JR et al. The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery. Cancer J. Sci. Am. 4, 110-124 (1998).
33. Schlegel U, Pels H, Glasmacher A et al. Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study. J. Neurol. Neurosurg. Psychiatry 71, 118-122 (2001).
34. Batchelor TT, Carson K, O'Neill A et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J. Clin. Oncol. 21(6), 1044-1049 (2003).
35. Herrlinger U, Schabet M, Brugger W et al. German Cancer Society Neuro-Oncology Working Group NOA-03 multi-center trial of single-agent high-dose methotrexate for primary CNS lymphoma. Ann. Neurol. 51(2), 247-252 (2002).
36. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J. Clin. Oncol. 18(17), 3144-3150 (2000).
37. Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-aids-related primary central nervous system lymphoma: European organization for research and treatment of cancer lymphoma group phase ii trial 20962. J. Clin. Oncol. 21, 4483-4488 (2003).
38. Omuro AM, DeAngelis LM, Yahalom J, Abrey LE. Chemoradiotherapy for primary CNS lymphoma: an intent-totreat analysis with complete follow-up. Neurology 64, 69-74 (2005).
39. Herrlinger U, Schabet M, Brugger W et al. Primary central nervous system lymphoma 1991-1997. Cancer 91, 130-135 (2001).
40. Batchelor TT, Kolak G, Ciordia R, Foster CS, Henson JW. High-dose methotrexate for intraocular lymphoma. Clin. Cancer Res. 9, 711-715 (2003).
41. Gabbai AA, Hochberg FH, Linggood RM, Bashir R, Hotleman K. High-dose methotrexate for non-AIDS primary central nervous system lymphoma. Report of 13 cases. J. Neurosurg. 70(2), 190-194 (1989).
42. O'Brien PC, Roos DE, Liew KH et al. Preliminary results of combined chemotherapy and radiotherapy for non-AIDS primary central nervous system lymphoma. Trans-Tasman Radiation Oncology Group (TROG). Med. J. Aust. 165(8), 424-427 (1996).
43. Ferreri AJ, Reni M, Pasini F et al. A multicenter study of treatment of primary CNS lymphoma. Neurology 58(10), 1513-1520 (2002).
44. DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J. Clin. Oncol. 10(4), 635-643 (1992).
45. Fliessbach K, Helmstaedter C, Urbach H et al. Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. Neurology 64, 1184-1188 (2005).
46. Fliessbach K, Urbach H, Helmstaedter C et al. Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma. Arch. Neurol. 60, 563-568 (2003).
47. Linnebank M, Pels H, Kleczar N et al. MTX-induced white matter changes are associated with polymorphisms of methionine metabolism. Neurology 64, 912-973 (2005).
48. Shibamoto Y, Tsutsui K, Dodo Y, Yamabe H, Shima N, Abe M. Improved survival rate in primary intracranial lymphoma treated by high-dose radiation and systemic vincristine-doxorubicin-cyclophosphamide-prednisolone chemotherapy. Cancer 65(9), 1907-1912 (1990).
49. Brada M, Hjiyiannakis D, Hines F, Traish D, Ashley S. Short intensive primary chemotherapy and radiotherapy in sporadic primary CNS lymphoma (PCL). Int. J. Radiat. Oncol. Biol. Phys. 40, 1157-1162 (1998).
50. Chamberlain MC, Levin VA. Adjuvant chemotherapy for primary lymphoma of the central nervous system. Arch. Neurol. 47(10), 1113-1116 (1990).
51. Neuwelt EA, Goldman DL, Dahlborg SA et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J. Clin. Oncol. 9(9), 1580-1590 (1991).
52. Rosenthal MA, Sheridan WP, Green MD, Liew K, Fox RM. Primary cerebral lymphoma: an argument for the use of adjunctive systemic chemotherapy. Aust. NZ J. Surg. 63(1), 30-32 (1993).
53. White JC. Reversal of methotrexate binding to dihydrofolate reductase by dihydrofolate. J. Biol. Chem. 254, 4772-4774 (1979).
54. Goulian M, Bleile B, Tseng BY. Methotrexate-induced misincorporation of uracil into DNA. Proc. Natl Acad. Sci. USA 77(4), 1956-1960 (1980).
55. Kumar P, Kisliuk RL, Gaumont Y, Freisheim JH, Nair MG. Inhibition of human dihydrofolate reductase by antifolyl polyglutamates. Biochem. Pharmacol. 38(3), 541-543 (1989).
56. McGuire JJ, Coward JK. Pteroylpolyglutamates: biosynthesis, degradation, and function. In: Folates and Pterins Vol. 1 Chemistry and Biochemistry of Folates. Blakley RL, Benkovic SJ (Eds), John Wiley, NY, USA 135-190 (1984).
57. Kamen BA, Capdevila A. Receptor-mediated folate accumulation is regulated by the cellular folate content. Proc. Natl Acad. Sci. USA 83(16), 5983-5987 (1986).
58. Antony AC, Kane MA, Portillo RM, Elwood PC, Kolhouse JF. Studies of the role of a particulate folate-binding protein in the uptake of 5-methyltetrahydrofolate by cultured human KB cells. J. Biol. Chem. 260(28), 14911-1497 (1985).
59. Kamen BA, Wang MT, Streckfuss AJ, Peryea X, Anderson RG. Delivery of folates to the cytoplasm of MA104 cells is mediated by a surface membrane receptor that recycles. J. Biol. Chem. 263(27), 13602-13609 (1988).
60. Chu E, Allegra C. Antifolates. In: Cancer Chemotherapy and Biotherapy, 2nd edition. Chabner BA, Longo DL, (Eds), Lippincott-Raven, Philadelphia, USA 109-147 (1996).
61. Fabre I, Fabre G, Goldman ID. Polyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitro. Cancer Res. 44, 3190-3195 (1984).
62. Fry DW, Anderson LA, Borst M, Goldman ID. Analysis of the role of membrane transport and polyglutamation of methotrexate in gut and the Ehrlich tumor in vivo as factors in drug sensitivity and selectivity. Cancer Res. 43(3), 1087-1092 (1983).
63. Galivan J, Johnson T, Rhee M, McGuire JJ, Priest D, Kesevan V. The role of folylpolyglutamate synthetase and gammaglutamyl hydrolase in altering cellular folyl- and antifolylpolyglutamates. Adv. Enzyme Regul. 26, 147-155 (1987).
64. Jolivet J, Chabner BA. Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. J. Clin. Invest. 72, 773-778 (1983).
65. Allegra CJ, Chabner BA, Drake JC. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J. Biol. Chem. 260, 9720-9726 (1985).
66. Kamen BA, Whyte-Bauer W, Bertino JR. A mechanism of resistance to methotrexate. NADPH but not NADH stimulation of methotrexate binding to dihydrofolate reductase. Biochem. Pharmacol. 32(12), 1837-1841 (1983).
67. Sirotnak FM, Chello PL, Moccio DM et al. Stereospecificity at carbon 6 of fomyltetrahydrofolate as a competitive inhibitor of transport and cytotoxicity of methotrexate in vitro. Biochem. Pharmacol. 28(19), 2993-2997 (1979).
68. Matherly LH, Seither RL, Goldman ID. Metabolism of the diaminoantifolates: biosynthesis and pharmacology of the 7-hydroxyl and polyglutamyl metabolites of methotrexate and related antifolates. Pharmacol. Ther. 35(1-2), 27-56 (1987).
69. Bleyer WA. New vistas for leucovorin in cancer chemotherapy. Cancer 63(Suppl. 6), 995-1007 (1989).
70. Goldman ID. A model system for the study of heteroexchange diffusion: methotrexatefolate interactions in L1210 leukemia and Ehrlich ascites tumor cells. Biochim. Biophys. Acta. 233(3), 624-634 (1971).
71. Qin D, Ma J, Xiao J, Tang Z. Effect of brain irradiation on blood-CSF barrier permeability of chemotherapeutic agents. Am. J. Clin. Oncol. 20(3), 263-265 (1997).
72. Morikawa N, Mori T, Abe T, Ghoda M, Takeyama M, Hori S. Pharmacokinetics of methotrexate in plasma and cerebrospinal fluid. Ann. Pharmacother. 31(10), 1153-1156 (1997).
73. Isacoff WH, Eilber F, Tabbarah H et al. Phase II clinical trial with high-dose methotrexate therapy and citrovorum factor rescue. Cancer Treat Rep. 62(9), 1295-1304 (1978).
74. Monjanel S, Rigault JP, Cano JP, Carcassonne Y, Favre R. High-dose methotrexate: preliminary evaluation of a pharmacokinetic approach. Cancer Chemother. Pharmacol. 3(3), 189-196 (1979).
75. Chungi VS, Bourne DW, Dittert LW. Drug absorption VIII: Kinetics of GI absorption of methotrexate. J. Pharm. Sci. 67(4), 560-561 (1978).
76. Evans WE, Pratt CB. Effect of pleural effusion on high-dose methotrexate kinetics. Clin. Pharmacol. Ther. 23(1), 68-72 (1978).
77. Wan SH, Huffman DH, Azarnoff DL, Stephens R, Hoogstraten B. Effect of route of administration and effusions on methotrexate pharmacokinetics. Cancer Res. 34(12), 3487-3491 (1974).
78. Creaven PJ, Cohen MH, Allen LM. Methotrexate plasma decay kinetics: possible alteration in patients undergoing gut sterilization. Br. J. Cancer 34(5), 571-575 (1976).
79. Valerino DM, Johns DG, Zaharko DS, Oliverio VT. Studies of the metabolism of methotrexate by intestinal flora. I. Identification and study of biological properties of the metabolite 4-amino-4-deoxy-N 10 -methylpteroic acid. Biochem. Pharmacol. 21(6), 821-831 (1972).
80. Jacobs SA, Stoller RG, Chabner BA, Johns DG. 7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. J. Clin. Invest. 57(2), 534-548 (1976).
81. Sholar PW, Baram J, Seither R, Allegra CJ. Inhibition of folate-dependent enzymes by 7-OH-methotrexate. Biochem. Pharmacol. 15 37(18), 3531-3534 (1988).
82. Calvert AH, Bondy PK, Harrap KR. Some observations on the human pharmacology of methotrexate. Cancer Treat Rep. 61(9), 1647-1656 (1977).
83. Henderson ES, Adamson RH, Oliverio VT. The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man. Cancer Res. 25(7), 1018-1024 (1965).
84. Wall SM, Johansen MJ, Molony DA, DuBose TD Jr, Jaffe N, Madden T. Effective clearance of methotrexate using high-flux hemodialysis membranes. Am. J. Kidney Dis. 28(6), 846-854 (1996).
85. Straw JA, Szapary D, Wynn WT. Pharmacokinetics of the diastereoisomers of leucovorin after intravenous and oral administration to normal subjects. Cancer Res. 44, 3114-3119 (1984).
86. Schwartz JI, Agrawal NG, Wong PH et al. Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients. J. Clin. Pharmacol. 41(10), 1120-1130 (2001).
87. Drinka PJ, Langer E. The Cockroft-Gault formula. J. Am. Geriatr. Soc. 37(8), 820 (1989).
88. Jelliffe RW, Jelliffe SM. Estimation of creatinine clearance from changing serum-creatinine levels. Lancet 2(7726), 710 (1971).
89. Jelliffe RW. Letter: Creatinine clearance: bedside estimate. Ann. Intern. Med. 79(4), 604-605 (1973).
90. Marx GM, Blake GM, Galani E et al. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann. Oncol. 15(2), 291-295 (2004).
91. Dooley MJ, Singh S, Rischin D. Rounding of low serum creatinine levels and consequent impact on accuracy of bedside estimates of renal function in cancer patients. Br. J. Cancer 90(5), 991-995 (2004).
92. Proudfoot AT, Krenzelok EP, Vale JA. Position paper on urine alkalinization. J. Toxicol Clin. Toxicol. 42(1), 1-26 (2004).
93. Hesketh PJ, Kris MG, Grunberg SM et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J. Clin. Oncol. 15, 103-109 (1997).
94. Campbell C, Bramwell V, Charette M, Oliver T. Role of colony-stimulating factor in patients receiving myelosuppressive chemotherapy for treatment of cancer. Curr. Oncol. 10(2), 102-126 (2003).
95. Alkins SA, Byrd JC, Morgan SK, Ward FT, Weiss RB. Anaphylactoid reactions to methotrexate. Cancer 77(10), 2123-2126 (1996).
96. Allegra CJ, Drake JC, Bell BA, Curt GA, Chabner BA. Measuring levels of methotrexate. N. Engl. J. Med. 313(3), 184 (1985).
97. Evans WE, Pratt CB, Taylor RH, Barker LF, Crom WR. Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients. Cancer Chemother. Pharmacol. 3(3), 161-166 (1979).
98. NCI Special Exception Protocol E. Special Exception Protocol for the use of Carboxypeptidase-G2 for MTX Toxicity. 1-12 (2004).
99. Widemann BC, Hetherington ML, Murphy RF, Balis FM, Adamson PC. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity. Cancer 76(3), 521-526 (1995).
100. Zhao R, Goldman ID. Resistance to antifolates. Oncogene 22(47), 7431-7457 (2003).
101. Diddens H, Niethammer D, Jackson RC. Resistance of human tumor cell lines to antifolates. Cancer Treat Rev. 11(Suppl. A) 37-41 (1984).
102. Wood MC, Alastair W. Intrinsic and acquired resistance to methotrexate in acute leukemia. N. Engl. J. Med. 335(14), 1041 (1996).
103. Domin BA, Grill SP, Bastow KF, Cheng YC. Effect of methotrexate on dihydrofolate reductase activity in methotrexate-resistant human KB cells. Mol. Pharmacol. 21(2), 478-482 (1982).
104. Domin BA, Grill SP, Cheng Y. Establishment of dihydrofolate reductase-increased human cell lines and relationship between dihydrofolate reductase levels and gene copy. Cancer Res. 43(5), 2155-2158 (1983).
105. Rice GC, Ling V, Schimke RT. Frequencies of independent and simultaneous selection of Chinese hamster cells for methotrexate and doxorubicin resistance. Proc. Natl Acad. Sci. USA 84, 9261 (1987).
106. Chabner BA, Young RC. Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. J. Clin. Invest. 52(8), 1804-1811 (1973).
107. DeVita VT, Hellman S, Rosenberg SA. Antimetabolites. In: Cancer Principles and Practice of Oncology. 6th Edition. Chu E, Mota AC (Eds). Lippincott Williams & Wilkins, Philadelphia, PA, USA 391-333 (2001).
108. Jahnke K, Korfel A, Martus P et al. On behalf of the German Primary Central Nervous System Lymphoma Study Group (GPCNSL-SG). High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann. Onc. 16(3), 445-449 (2005).
109. Dorr RT, Von Hoff DD. Methotrexate. In: Cancer Chemotherapy Handbook. 2nd Edition. East Norwalk, Appleton & Lange, CT, USA 698-701 (1994).
110. Perry MC, Yarbro JW. Renal and Metabolic Toxicities of Cancer Treatment. In: Toxicity of Chemotherapy. Schilsky RL (Ed). Grune & Stratton, Inc. Orlando, FL, USA 325-326 (1984).
111. Shinozaki T, Watanabe H, Tomieokoro R. Successful rescue by oral cholestyramine of a patient with methotrexate nephrotoxicity: nonrenal excretion of serum methotrexate. Med. Pediatr. Oncol. 34, 226-228 (2000).
112. Perry MC: Hepatotoxicity of chemotherapeutic agents. Semin. Oncol. 9, 65-74 (1982).
113. Yang C, Yang LJ, Jaing TH et al. Toxic epidermal necrolysis following combination of methotrexate and trimethoprim-sulfamethoxazole. Int. J. Dermatol. 39, 621-623 (2000).
114. Doyle LA, Berg C, Bottion G et al. Erythema and desquamation after high-dose methotrexate. Ann. Intern. Med.. 98, 611-612 (1983).
115. Moller H. Reactivation of acute inflammation by methotrexate. J. Invest. Dermatol. 52, 437-441 (1969).
116. Korossy KS, Hood AF. Methotrexate reactivation of sunburn reaction. Arch. Dermatol. 117, 310-301 (1981).
117. Corder MP, Stone WH. Failure of leucovorin rescue to prevent reactivation of a solar burn after high dose methotrexate. Cancer 37, 1660-1662 (1976).
118. Glass J, Gruber ML, Cher L, Hochberg FH. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J. Neurosurg. 81, 188-195 (1994).
119. Abrey LE, Moskowitz CH, Mason WP et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J. Clin. Oncol. 21, 4151-4156 (2003).
120. Bertino JR. Leucovorin rescue revisited. J. Clin. Oncol. 8(2), 193-195 (1990).
121. Bessell EM, Graus F, Lopez-Guillermo A et al. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. Int. J. Radiat. Oncol. Biol. Phys. 59, 501-508 (2004).
122. Bessell EM, Graus F, Punt JA et al. Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy. J. Clin. Oncol. 14(3), 945-954 (1996).
123. Bessell EM, Lopez-Guillermo A, Villa S et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J. Clin. Oncol. 20, 231-236 (2002).
124. Bleyer WA. Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev. 4(2), 87-101 (1977).
125. Brada M, Dearnaley D, Horwich A, Bloom HJ. Management of primary cerebral lymphoma with initial chemotherapy: preliminary results and comparison with patients treated with radiotherapy alone. Int. J. Radiat. Oncol. Biol. Phys. 18(4), 787-792 (1990).
126. Breithaupt H, Kuenzlen E. Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate. Cancer Treat Rep. 66(9), 1733-1741 (1982).
127. Calvert AH. Folate status and the safety profile of antifolates. Semin. Oncol. 29(Suppl. 5), 3-7 (2002).
128. Chabner BA, Allegra CJ, Curt GA et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J. Clin. Invest. 76(3), 907-912 (1985).
129. Correa DD, DeAngelis LM, Shi W, Thaler H, Glass A, Abrey LE. Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 62, 548-555 (2004).
130. Deangelis LM, Horringo A. Treatment of primary central nervous system lymphoma. Semin. Oncol 11(5), 684-689 (2004).
131. Doolittle ND, Petrillo A, Bell S, Cummings P, Eriksen S. Blood-brain barrier disruption for the treatment of malignant brain tumors: the national program. J. Neurosci. Nurs. 30, 81-90 (1998).
132. Ferreri AJ, Dell'Oro S, Capello D et al. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas. Br. J. Haematol.126, 657-664 (2004).
133. Ferreri AJ, Guerra E, Regazzi M et al. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br. J. Cancer 90, 353-358 (1996).
134. Fleming RA, Eldridge RM, Johnson CE, Stewart CF. Disposition of high-dose methotrexate in an obese cancer patient. Cancer 68(6), 1247-1250 (1991).
135. Freilich RJ, Delattre JY, Monjour A, DeAngelis LM. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 46, 435-439 (2004).
136. Glass J, Gruber ML, Cher L, Hochberg FH. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J. Neurosurg. 81, 188-195 (1994).
137. Goldman ID, Matherly LH. The cellular pharmacology of methotrexate. Pharmacol. Ther. 28(1), 77-102 (1985).
138. Hoang-Xuan K, Taillandier L, Chinot O et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J. Clin. Oncol. 21, 2726-2731 (1994).
139. Jahnke K, Thiel E, Schilling A et al. Low-grade primary central nervous system lymphoma in immunocompetent patients. Br. J. Haematol. 128, 616-624 (2003).
140. Kepka L, De Lassence A, Ribrag V et al. Successful rescue in a patient with high dose methotrexate-induced nephrotoxicity and acute renal failure. Leuk. Lymphoma. 29(1-2), 205-209 (1998).
141. O'Brien PC, Roos DE, Pratt G et al. Combined-modality therapy for primary central nervous system lymphoma: long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group). Int. J. Radiat. Oncol. Biol. Phys. 27 (2005) [Epub ahead of print].
142. Park DM, Abrey LE. Pharmacotherapy of primary CNS lymphoma. Expert Opin. Pharmacother. 3(1), 39-49 (2002).
143. Plotkin SR, Batchelor TT. Primary nervous-system lymphoma. Lancet Oncol. 2, 354-365 (2001).
144. Soussain C, Hoang-Xuan K, Levy V. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. Bull Cancer 91, 189-192 (2004).
145. Micromedex® Healthcare Series: Thomson Micromedex, Greenwood Village, Colorado (Edition expires Apr, 2006). Accessed Oct 2005. www.micromedex.com
146. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Accessed Oct 2005. www.nccn.org.